Trials / Unknown
UnknownNCT03649945
Endostatin Combined With Chemotherapy for Adjuvant Treatment of Esophageal Cancer
An Open-label, Randomized Clinical Trial of Recombinant Human Endostatin (Endo) Combined With Chemotherapy Compared With Chemotherapy for Adjuvant Treatment of Esophageal Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 186 (estimated)
- Sponsor
- First Affiliated Hospital of Guangxi Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, randomized trial, it compares the efficacy and safety between apatinib combined chemotheray and chemotherapy for adjuvant treatment of esophageal cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Docetaxel | 75mg/m2，3 weeks for one cycle，dosed on the first day of every cycle,totally 6 cycles |
| DRUG | Nedaplatin | 80 mg/m2,3 weeks for one cycle，dosed on the first day of every cycle,totally 6 cycles |
| DRUG | Endostar | 7.5mg/m2，once a day, continuously dosed for 14 days, then stop for 7 days,3 weeks for one cycle, totally 6 cycles |
Timeline
- Start date
- 2018-11-01
- Primary completion
- 2020-11-01
- Completion
- 2021-05-01
- First posted
- 2018-08-28
- Last updated
- 2018-08-28
Source: ClinicalTrials.gov record NCT03649945. Inclusion in this directory is not an endorsement.